NeuroPace Reports Third Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 11/08/22
NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)Business Wire • 10/11/22
NeuroPace to Present at the Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 08/23/22
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22
NeuroPace Reports Second Quarter 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/11/22
NeuroPace Announces Distribution Agreement with DIXI Medical USA, Provider of Intracranial Electrodes and Instruments for NeurosurgeryGlobeNewsWire • 08/11/22
NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/14/22
NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare ConferenceGlobeNewsWire • 05/13/22
NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in AdolescentsBusiness Wire • 05/04/22
NeuroPace, Inc. (NPCE) CEO Mike Favet on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/10/22
NeuroPace to Report Fourth Quarter and Full Year 2021 Financial Results and Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 01/27/22
NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 RevenueGlobeNewsWire • 01/11/22
NeuroPace, Inc.'s (NPCE) CEO Mike Favet on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/10/21
NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized EpilepsyGlobeNewsWire • 11/10/21
NeuroPace to Report Third Quarter 2021 Financial Results on November 10, 2021GlobeNewsWire • 10/20/21